68Ga-prostate-specific membrane antigen PET/CT (68Ga-PSMA PET/CT) offers
unprecedented accuracy for staging of primary, persistent, or recurrent prostate cancer …

The present study analyzed the impact of 68Ga-labeled prostate-specific membrane antigen-
HBED-CC (68Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of …

The objective of this study was to assess the impact of 68Ga-prostate-specific membrane
antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with …

The impact of prostate-specific membrane antigen (PSMA) PET/CT on management of
prostate cancer (PCa) patients with biochemical recurrence (BCR) is well established …

Objectives This retrospective study aimed to evaluate the role of 68 Ga-PSMA-I&T PET/CT in
the primary staging of newly diagnosed prostate cancer (PCa), with a focus on the detection …

Purpose To assess the association between PSA levels, PSA kinetics and other factors and
a pathological 68 Ga-PSMA PET/CT scan in patients with recurrent prostate cancer (rPCa) …

Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

Introduction The management of prostate cancer has undergone significant advances since
the introduction of 68Ga‐prostate‐specific membrane antigen (68Ga‐PSMA) positron …

Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients, as
recurrence localization guides subsequent therapies. The use of PET with prostate-specific …

Background To determine the potential role of 68 Ga-PSMA positron emission
tomography/computed tomography (PET/CT) in radiotherapy (RT) planning for prostate …